Target discovery & immunotherapy design solutions
Target discovery service for immunotherapy programs: antigen discovery, immunogenicity, product design, and analysis. Modular solutions used independently or…
myneotx.comCrawled Nov 17, 2026
Target discovery service for immunotherapy programs: antigen discovery, immunogenicity, product design, and analysis. Modular solutions used independently or…
ImmunoEngine integrates whole-genome sequencing, neoMS presentation prediction, and neoIM immunogenicity scoring instead of mutation lists or MHC binding scores.
ImmunoEngine is myNEO's antigen discovery pipeline. neoMS predicts MHC presentation, neoIM scores immunogenicity, and camyotopes are dark-genome tumor antigens.
myADA by myNEO Therapeutics: next-generation in-silico anti-drug antibody (ADA) risk prediction using MHC class II immunogenicity modeling for biologics design.
mySELF by myNEO Therapeutics: immunogenic and tolerogenic self-antigen prediction for autoimmune disease target discovery across CD8 and CD4 contexts.
mySURFACE identifies and prioritizes transmembrane targets and target pairs from cancer expression data for antibody, ADC, and T-cell engager programs.
myNEO Therapeutics’ CEO, Cedric Bogaert, discusses the CAMYO-01 program, a shared colorectal cancer vaccine.
Lymfklierkanker Vereniging Vlaanderen (LVV) is organizing a webinar where Lien Lybaert will explain in understandable language to cancer patients.
neoIM is the first-in-class immunogenicity predictor with high accuracy in identifying which neoantigens are capable of eliciting a T-cell response.
The page cites peer-reviewed papers, technology papers, and whitepapers on neoantigen discovery and immunogenicity prediction.
myNEO Therapeutics published a review paper in *Cancer Cell* authored by colleagues Lien and Steve.
myNEO Therapeutics and VIB collaborate on a strategic partnership to advance novel breast cancer drugs into clinical development.
Arcturus Therapeutics (NASDAQ: ARCT, San Diego) has entered into a definitive agreement to acquire myNEO, subject to customary closing conditions.
myNEO Therapeutics marks a milestone in the NEOVACC Phase I clinical trial, with the first patient receiving a personalized cancer vaccine.
Time matters in personalized immunotherapy: every day saved between biopsy and treatment is a day gained for the patient.
News, partnerships, publications, and events from myNEO Therapeutics on antigen discovery, ImmunoEngine, and immune-driven therapy programs.
Careers at myNEO Therapeutics in Ghent. No open roles are listed now; send a spontaneous application with a cover letter and resume to hr@myneotx.com.
Bert Coessens, Chief Operating Officer at myNEO Therapeutics, has a background in molecular biology and a PhD in advanced statistical methods.
Cedric Bogaert, Chief Executive Officer and Co-founder of myNEO Therapeutics, graduated as a Bioscience Engineer at Ghent University, majoring in medical biology.
Em. Prof. Kris Thielemans, Scientific Advisor at myNEO Therapeutics, began his research career in a laboratory setting.
Emiel Evenepoel, Principal Data Scientist at myNEO Therapeutics, holds a bachelor’s in Biology from the University of Ghent and a Master’s in Bioinformatics.
Gitta Boons, Senior Data Scientist at myNEO Therapeutics, studied Biochemistry and Biotechnology at the University of Antwerp.
Jan Van den Berghe, Co-founder of myNEO Therapeutics, is a serial entrepreneur in the food and biotech industries.
myNEO Therapeutics is a Ghent-based biotech specializing in antigen discovery and immune-target design for immunotherapy solutions.
myNEO Therapeutics offers solutions, demonstrations, partnerships, and licensing for vaccine, T-cell, and biologics programs.
Neoantigen discovery service and target discovery for vaccine, T-cell, and biologics programs. ImmunoEngine antigen discovery and modular immunogenicity,…